Member

Ranko Škrbic



CURRICULUM VITAE 

 

Ranko Škrbic, MD; M.Sc.; Ph.D.

Specialist in Clinical Pharmacology

 

Personal

Born April 10, 1961, Banja Luka, Bosnia & Herzegovina,

 two daughters: Nina (1989) and Natasa (1994)

 

Nationality

Serbian, Bosnia & Herzegovina

 

Core Education (Degree)

1981-1986                   Faculty of Medicine, University of Banja Luka, B&H, Yugoslavia

Graduate study, (MD)

1987-1989         Faculty of Medicine, University of Zagreb, Croatia

Postgraduate Study (M.Sc.)

1989-1990                   Department of Pharmacology, Schinshu University School of Medicine, Matsumoto, Japan; Japanese Government Research fellowship

1994                               University of Belgrade, School of Medicine, Belgrade, Serbia; PhD study. (PhD degree)

1995-2000         Faculty of Medicine, University of Novi Sad, Serbia

                           Specialization in Clinical Pharmacology (Specialist)

 

Short term courses and trainings

1999                   Drug information training, Bristol Royal Infirmary, Bristol, UK

2000                   Course in Pharmacoeconomics, London School of Economics (LSE), London, UK

2002                                     Training in Health management, Training of trainers program, Institute for Health management, Banja Luka in collaboration with Imperial College London and Heidelberg University (World bank ; Basic  Health Project for B&H)

 

Scientific degrees

 

Master thesis ( M. Sc., Biology) Faculty of Medicine, Zagreb University, 1991: 

   “The role of E.coli endotoxin treatment on urinary kallikrein excretion in rats”

 

Doctor thesis (PhD, Pharmacology) Faculty of Medicine, Belgrade University, 1994:

            “The presence of adrenergic, serotoninergic, cholinergic and VIP receptors in dog and monkey lingual arteries”

 

 

 

Professional appointments

 

1986-1987                   GP, Primary Health Care Center, Laktasi, Banja Luka

1987-1991         Teaching Assistant, Department of Pharmacology,
Faculty of Medicine, University of Banja Luka

1989-1994                   Research Assistant, Department of Pharmacology,
Faculty of Medicine, University of Banja Luka

1994-2002         Assistant Professor of Pharmacology,

                           Faculty of Medicine, University of Banja Luka

2002-2009         Associate Professor of Pharmacology, and

                           Head of Department of Pharmacology,
Faculty of Medicine, University of Banja Luka

1998-2006         Head of National Drug Information Centre, Department of Clinical Pharmacology, established in collaboration with WHO and EU-ECHO          

1997-1999         Chairman of Drug Committee, Ministry of Health of Republic of Srpska

1999-2002         Chairman of Drug Registration Committee of Republic of Srpska

1998-1999                  EU PHARE Regional Coordinator for Pharmaceutical Sector Development in Bosnia and Herzegovina. Local consultant to Stockholm Care; Stockholm, Sweden.

1999-2000         UNICEF Regional Coordinator for Essential Drugs and Rational drug use in Republik of Srpska (BiH),

2000-2002                   EU-CARDS  Regional Coordinator for Health Care Reform in Bosnia and Herzegovina. Local consultant to Maxwell Stamp, London, UK.

2000-2003                   Chairman of Positive Drug List Committee, Health Insurance Fund of Republic of Spbska

2001-2003         Short term consultant for Development of Accreditation Standards and Clinical Guidelines, EPSILON Research, Development and Consulting, doo, Banja Luka (Basic health Project of the World Bank; Accreditation and Quality Assurance)

2002-2004         Director of Institute for Health Management, Banja Luka, RS, BiH

2009                               Professor of Pharmacology and Clinical Pharmacology, Faculty of  Medicine, University of Banja Luka

2006-2013         Minister of Health and Social Welfare, Government of Republic of Srpska, BiH

2013- now         Ambassador of Bosnia & Herzegovina in Serbia

                                   


 

Membership in professional Societies

 

·         Member of the Council of European Association for Clinical Pharmacology and Therapeutics  (EACPT)

·         Member of the Serbian pharmacological society

·         Member of the Section for toxicology of the Serbian Medical Association

·         Member of the Section for clinical pharmacology of the Serbian Medical Association

·         Member of the Association of Clinical Pharmacological Societies with Sections of Clinical Pharmacists and Pharmacoinformatics of Bosnia and Herzegovina

 

 

 

 

PROFESSIONAL EXPERIENCE

 

               

Intersectorial collaboration on health

-          Comprehensive understanding of governmental and intersectorial processes, procedures and policy making for health

-          Experience in work with intersectorial mechanisms for health (transportation, HIV/AIDS, social policies)

-          Ability and skills to effectively advocate for health across different sectors (industry, transportation, agriculture finance, etc.)

 

Health policy

-          Experience in Global and International health governance

-          Health policy and strategy (policy and strategy development, implementation, monitoring and evaluation)

-          Health planning (strategic and operational planning)

-          Organization and implementation of policy dialogues 

-          Health management

-          Public health

 

Clinical Pharmacology

-          Professional teaching in pharmacology and clinical pharmacology

-          Clinical trials

-          Drug utilization analysis

-          Rational drug prescribing and drug interactions

 

Pharmaceutical policy

-          National drug policy (quality assurance, pricing policy, reimbursement policy)

-          Drug management (promotion and marketing, procurement and distribution)

-          Promotion of essential drugs program

-          Development and implementation of standard treatment guidelines

-          Drug information service and drug bulletins

 

Diplomacy and political skills

-          Understanding and knowledge of diplomatic protocol

-          Knowledge, skills and direct participation in bilateral and multilateral negotiations

-          Diplomatic communication skills

-          Comprehensive understanding of political dynamics and situation in the region

 

 

Organization of conferences

-          Chairman of the 6th Xenobiotic Metabolism and Toxicity Workshop of Balkan Countries, Banja Luka, Bosnia & Herzegovina, June 16-20, 2004

 

-          Charring The Third Health Ministers’ Forum - Health in All Policies in South-eastern Europe: a Shared Goal and Responsibility ; 13-14 October 2011, Banja Luka, Republic of Srpska, B&H.
The Banja Luka Pledge (2011) was signed to that effect.

 

 

Others

-          Participation in World Health Assembly of WHO, Geneva

-          Participation to the Special Session of UN General Assembly on NCD, New York

-          Participation in WHO EURO Regional Committees: Copenhagen, Moscow, Baku, Valletta

-          Participation in SEEHN meetings

 

Language skills

·         Serbian (native language),

·         English (reading, speaking, writing)

 

 

 

 

 

 

 

 


PUBLICATIONS

 

Selected papers cited in Current Contents

 

 

1.        Skrbic R, Chiba S. Pharmacological features of vascular responses of isolated dog and monkey lingual arteries to vasoactive substances. Jpn J Pharmacol 1991; 57(1):99-107

2.        Skrbic R, Chiba S. Pharmacological properties of alpha 1-adrenoceptor-mediated vasoconstrictions in dog and monkey lingual arteries: evidence for subtypes of alpha 1-adrenoceptors. Heart Vessels 1992;7(2):82-90.

3.        Skrbic R, Chiba S. Dominant antagonistic action of alpha 2-adrenoceptor agonists on alpha 1-agonist-induced vasoconstriction. Eur J Pharmacol 1993; 230(2):131-7.

4.        Skrbic R, Babic-Djuric D, Stoisavljevic-Satara S,  Stojakovic N, Nezic L. The role of drug donations on hospital use of antibiotics during the war and postwar period. Int J Risk Safety Med, 2001; 14(1-2):31-40.

5.        Petrova GI, Linari D, Hojer B, Skrbic R, Sarkic i, Falkenberg T. Towards improving pharmaceutical equity in transition in Bosnia & Herzegovina.
J Soc Adm Pharm 2002; 19(1):15-24.

6.        Verhaz A, Škrbic R, Rakic-Music M, Sabo A. Catheter-related urinary infections at the Clinical Center in Banja Luka. Med Pregl 2003; 56(9-10):460-464.

7.        Stojiljkovic Lj, Alexander B, Stoisavljevic-Šatara, Škrbic R, Igic R. Glycosidase activities in hog serum, optoc nerve, and ocular tissues. Biochemical Research 25(2): 101-103, 2004

8.        Stojakovic N, Škrbic R, Stoisavljevic-Šatara S, Babic-Djuric D, Nezic L, Sabo A. Prescription-only drugs in Banja Luka region:Utilization analysis. Med Pregl, 2004; 57:1-2:72-76

9.        Verhaz A, Škrbic R, Rakita-Music M. Rezistencija na antibakterijske lijekove kod infekcija urinarnog trakta nastalih zbog primjene urinarnih katetera. Vojnosanit Pregl 2005; 62(3):181-7

10.    Raskovic A, Mikov M, Skrbic R, Jakovljevic V, Vasovic V, Posa M, Kuhajda K, Kevresan S, Tomic Z, Siladji Dj. Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglicemic and diabetic rats. Eur J Drug Metab Pharmockinetics, 2008; 33(1):17-22.

11.    Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. Probiotic treatment proceeded by a single dose of bile acide and gliclazide exert the most hypoglycemic affect in type 1 diabetic rats. Med Hypotheses and Res, 2008; 4(2):93-101.

12.    Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, Mikov M. Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Info, 2008

13.    Mikov M, Al-Salami H, Golocorbin-Kon S, Skrbic R, Raskovic A, Fawcett JP. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 2008;33(3):137-42

14.    Nezic L, Skrbic R, Dobric S, Stoljiljkovic PM, Jacevic V, Stoisavljevic Satara S, Milovanovic AZ, Stojakovic N. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol, 2009; 104:185-91.

15.    Markovic-Pekovic V, Stoisavljevic-Satara S, Škrbic R. Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, five years study. Pharmacol Drug Safety, 2009; 18:320-326.

16.    Markovic-Pekovic V, Škrbic R, Grubšsa N. The pharmaceutical sector in the Republic of Srpska, Bosnia and Herzegovina. Eurohealth, 2009; 15(1):23-26.

17.    Nezic L, Škrbic R, Dobric S, Stojiljkovic M, Z Milovanovic, V Jacevic, S Stoisavljevic-Šatara, Stojakovic N. Effect of simvastatin on proinflammatory cytokines production in rats during lipopolysaccharide-induced inflammation. Gen Physiol Biophys 2009;28:119-26.

18.    Škrbic R, Igic R. Seven decades of angiotensin discovery (1939-2009). Peptides 2009; 30:1945-50.

19.    Appiah I, Milovanovic S, Radojicic R, Nikolic-Kokic A, Orešcanin-Dušic Z, Slavic M, Trbojevic S, Škrbic R, Spasic MB, Blagojevic D. Hydrogen peroxide affects contractile activity and anti-oxidant enzymes in rat uterus. Br J Pharmacol. 2009; 158(8):1932-41.

20.    Markovic-Pekovic V, Stoisavljevic-Satara S, Skrbic R. Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. Eur J Clin Pharm, 2010; 66:177-186.

21.    Vulic D, Loncar S, Krneta M, Škrbic R, Lee BT, Lopez VA, Wong ND. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. Arch Med Sci, 2010; 6(2):183-7.

22.    Sokolova-Djokic L, Miloševic S, Škrbic R, Salabat R, Voronov G, Igic R. Pulse carboxyhemoglobin-oximetry and cigarette smoking. J BOUN. 2011; 16(1):170-3.

23.    Markovic-Pekovic V, Skrbic R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):661-71

24.    Mandić D, Nezić L, Skrbić R. Severe hyperkalemia induced by propranolol. Med Pregl. 2014; 67(5-6):181-4.

25.    Igić R, Škrbić R. The renin-angiotensin system and its blockers. Srp Arh Celok Lek. 2014; 142(11-12):756-63.

 

 

 

 

 

 

 

Papers published in extenso in national journals

 

  1. Stojisavljevic-Satara S, Skrbic R, Nikolic J, Djuric D. Protective effects of acetylsalicylic acid pretreatment on gentamicin-induced nephrotoxicity in rats. Arch Toxicol Kinet Xenobiot Metab 1997; 5 (3): 363-370.

2.      Skrbic R, Stoisavljevic-Satara S, Igic R. Effects of E.coli endotoxin treatment and acetylsalicylic acid pretreatment on urinary kallikrein excretion. Arch Toxicol Kinet Xenobiot Metab 1996; 4(1): 43-49.

3.      Stojiljkovic MP, Skrbic R, N Pavlovic, S Romanic. Nerve gases as means of chemical terrorism in Japan. Arch Toxicol Kinet Xenobiot Metab 1997; 5(4):371-83.

4.      Stoisavljevic-Šatara S, Škrbic R, Nikolic J, Amidzic Lj, Stojakovic N, Nezic L. Protektivno djelovanje apafanta na nefrotoksicnost izazvanu cisplatinom kod pacova. Scr Med 2002; 33(2): 65-72.


BOOKS AND MONOGRAPHS

 

·           Stanulovic M, Sabo A, Jakovljevic V, Škrbic R, Stoisavljevic-Šatara S.
LIJEKOVI U PROMETU, REPUBLIKA SRPSKA, PRIRUČNIK O LIJEKOVIMA I NJIHOVOJ PRIMJENI, Banja Luka Ortomedics, 1998.

 

·           Skrbic R, Stojisavljevic-Satara S. ESSENTIAL DRUGS OF REPUBLIC OF SRPSKA (in Serbian), Banja Luka Medicinski fakultet, 1999.

 

·           Stanulovic M, Sabo A, Jakovljevic V, Škrbic R, Stoisavljevic-Šatara S.
LIJEKOVI U PROMETU, REPUBLIKA SRPSKA, PRIRUČNIK O LIJEKOVIMA I NJIHOVOJ PRIMJENI, Banja Luka Ortomedics, 2000.

 

·           Balaban B, Skrbic R, Jelic G. HEALTH CARE EXPENDITURES IN REPUBLIKA SRPSKA IN 2000; SURVEY ON HEALTH CARE EXPENDITURES, PERCEPTIONS OF POPULATION ON HEALTH CARE, AND FAMILY MEDICINE CABINETS ANALYSIS. Banja Luka: Faculty of Medicine, 2001.

·           Skrbic R, Markovic-Pekovic V, Stoisavljevic-Satara S, Babic-Djuric D.
ATC CLASSIFICATION AND DRUG UTILIZATION ANALYSIS BY DDD METHODOLOGY FOR THE DRUGS REGISTERED IN REPUBLIKA SRPSKA (in Serbian). Medicinski fakultet, Banja Luka, 2001.

·           Skrbic R, Markovic-Pekovic V, Stoisavljevic-Satara S, Mikov M, Stanulovic M. REGISTAR OF DRUGS IN REPUBLIC OF SRPSKA, 2002, (in Serbian).

·           Stoisavljevic-Šatara S, Škrbic R. IZBOR LIJEKOVA ZA BOLESTI RESPIRATORNOG SISTEMA. U: Stanetic M, urednik. Pulmološki prirucnik. Banja Luka: Medicinski fakultet, 2002: 249-290.

·           Škrbo A, Pandzo J, Šabaredzovic M, Škrbic R, Stoisavljevic-Šatara S. LIJEKOVI U BOSNI I HERCEGOVINI. Sarajevo: Medjukantonalna farmaceutska komora federacije BiH i Zavod za farmakologiju i toksikologiju Medicinski fakultet Banja Luka, 2003.

·           Skrbic R, Markovic-Pekovic V, Stoisavljevic-Satara S, Grubisa N, Tubic B.
ATC CLASSIFICATION AND DRUG UTILIZATION ANALYSIS BY DDD METHODOLOGY FOR THE DRUGS REGISTERED IN REPUBLIKA SRPSKA (in Serbian). Medicines Agency of Republic of Srpska, Banja Luka, 2007.

·           Mikov M, Škrbic R, Fawcett JP. SULPHASALAZINE - PAST, PRESENT AND FUTURE CHALLENGES. Medical Faculty, University of Banja Luka, 2009.

·           Trkulja V, Ostojic I, Škrbic R, Herceg N, Petrovic D, Kovacevic Z. AMBROZIJA. Društvo za zaštitu bilja u bosni i Hercegovini. Banja Luka. Banja Luka 2010.

·           Igic R, Škrbic R. KAKO SE PIŠU I PUBLIKUJU SAOPŠTENJA O BIOMEDICINSKIM ISTRAZIVANJIMA. Grafomark, Laktaši, 2012.

 


AIK Banka     Comtrade     Crowne Plaza Belgrade     Delta Auto     Erste Bank     MK Commerce     Advokatska kancelarija Stevanović

© Copyright 2015 Ti Computers Solutions

East-West Bridge
Prizrenska 13
T: +381 11 2681751 | T: +381 11 2658690


Contact: Milica Krstic +381 11 2681751 , milica.krstic@ewb.rs
'